Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen

The SARS-Cov-2 (COVID-19) pandemic remains a major worldwide public health issue. Initially, improved supportive and anti-inflammatory intervention, often employing known drugs or technologies, provided measurable improvement in management. We have recently seen advances in specific therapeutic interventions and in vaccines. Nevertheless, it will be months before most of the world's population can be vaccinated to achieve herd immunity. In the interim, hyperbaric oxygen (HBO2) treatment offers several potentially beneficial therapeutic effects. Three small published series, one with a propensity-score-matched control group, have demonstrated safety and initial efficacy. Additional anecdotal reports are consistent with these publications. HBO2 delivers oxygen in extreme conditions of hypoxemia and tissue hypoxia, even in the presence of lung pathology. It provides anti-inflammatory and anti-proinflammatory effects likely to ameliorate the overexuberant immune response common to COVID-19. Unlike steroids, it exerts these effects without immune suppression. One study suggests HBO2 may reduce the hypercoagulability seen in COVID patients. Also, hyperbaric oxygen offers a likely successful intervention to address the oxygen debt expected to arise from a prolonged period of hypoxemia and tissue hypoxia. To date, 11 studies designed to investigate the impact of HBO2 on patients infected with SARS-Cov-2 have been posted on clinicaltrials.gov. This paper describes the promising physiologic and biochemical effects of hyperbaric oxygen in COVID-19 and potentially in other disorders with similar pathologic mechanisms.

Performance characteristics of high-frequency percussive ventilation under hyperbaric conditions

INTRODUCTION

Safe administration of critical care hyperbaric medicine requires specialized equipment and advanced training. Equipment must be tested in order to evaluate function in the hyperbaric environment. High-frequency percussive ventilation (HFPV) has been used in intensive care settings effectively, but it has never been tested in a hyperbaric chamber.

METHODS

Following a modified U.S. Navy testing protocol used to evaluate hyperbaric ventilators, we evaluated an HFPV transport ventilator in a multiplace hyperbaric chamber at 1.0, 1.9, and 2.8 atmospheres absolute (ATA). We used a test lung with analytical software for data collection. The ventilator uses simultaneous cyclic pressure-controlled ventilation at a pulsatile flow rate (PFR)/oscillatory continuous positive airway pressure (oCPAP) ratio of 30/10 with a high-frequency oscillation percussive rate of 500 beats per minute. Inspiratory and expiratory times were maintained at two seconds throughout each breathing cycle.

RESULTS

During manned studies, the PFR/oCPAP ratios were 26/6, 22/7, and 22.5/8 at an airway resistance of 20cm H2O/L/second and 18/9, 15.2/8.5, and 13.6/7 at an airway resistance of 50 cm/H2O/L/second at 1, 1.9, and 2.8 ATA. The resulting release volumes were 800, 547, and 513 mL at airway resistance of 20 cm H2O/L/sec and 400, 253, and 180 mL at airway resistance of 50 cm/H2O/L/sec at 1, 1.9, and 2.8 ATA. Unmanned testing showed similar changes. The mean airway pressure (MAP) remained stable throughout all test conditions; theoretically, supporting adequate lung recruitment and gas exchange. A case where HFPV was used to treat a patient for CO poisoning was presented to illustrate that HFPV worked well under HBO2 conditions and no complications occurred during HBO2 treatment.

CONCLUSION

The HFPV transport ventilator performed adequately under hyperbaric conditions and should be considered a viable option for hyperbaric critical care. This ventilator has atypical terminology and produces unique pulmonary physiology, thus requiring specialized training prior to use.

ARTERIAL INSUFFICIENCIES: Hyperbaric Oxygen Therapy for Selected Problem Wounds

The use of hyperbaric oxygen (HBO2) for the treatment of selected problem wounds has focused almost entirely on the diabetic foot ulcer (DFU) in recent years. The prevalence of DFUs in today's patient population and the reimbursement available for the treatment of DFUs have given it priority status in discussions about problem wounds, but there are sound fundamental reasons why additional oxygen may have benefits in the treatment of non-DFU wounds.

Impact of Hyperbaric Oxygen on More Advanced Wagner Grades 3 and 4 Diabetic Foot Ulcers: Matching Therapy to Specific Wound Conditions

Objective: The goal of this research was to identify a population of diabetic foot ulcer patients who demonstrate a significant response to hyperbaric oxygen therapy (HBOT) using a large sample size to provide guidance for clinicians when treating these complicated patients. Approach: The effect of HBOT on diabetic foot ulcers, Wagner grades 3 and 4, was evaluated using a retrospective observational real-world data set. The study reported on the overall healing rate, (74.2%) at the population level, for >2 million wounds. Results: When a subgroup of patients of only foot ulcers with a Wagner grade 3 or 4 were considered, the healing rate was only 56.04%. The use of HBOT, without filtering for the number of treatments received, improved the healing rate to 60.01% overall. Healing rates for this same subgroup, however, were improved to 75.24% for patients who completed the prescribed number of hyperbaric treatments. Innovation: This observational study discusses the importance of reporting at the population level, specific wound etiology level, a risk-stratified level, and to then overlay the effect of treatment adherence on those outcomes to provide clinicians with a comprehensive understanding of when to prescribe an advanced modality such as hyperbaric oxygen. Conclusion: The authors provide healing outcomes data from several prior HBOT studies as well as other advanced modalities that have been used in diabetic foot ulcer care for comparison and context.

Hyperbaric medicine today: an historically noble discipline challenged by loss of critical access and overutilization -- an introduction to invited commentary

The field of undersea and hyperbaric medicine has changed since the day six Naval officers established the Undersea Medical Society in 1967. At that time, the focus of the field primarily involved the treatment of emergencies, but over the next 50 years, the UHMS has promulgated the use of hyperbaric oxygen (HBO2) therapy for many additional indications. The field of hyperbaric medicine has grown to include more than the treatment of emergent indications, and as the interest in using HBO2 for non-healing wounds increased, the number of facilities available for emergency and critical care hyperbaric oxygen therapy has dropped. There are numerous reasons for this.

A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers

BACKGROUND

The role of hyperbaric oxygen (HBO2) for the treatment of diabetic foot ulcers (DFUs) has been examined in the medical literature for decades. There are more systematic reviews of the HBO2/DFU literature than there have been randomized controlled trials (RCTs), but none of these reviews has resulted in a clinical practice guideline (CPG) that clinicians, patients and policy-makers can use to guide decision-making in everyday practice.

METHODS

The Undersea and Hyperbaric Medical Society (UHMS), following the methodology of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, undertook this systematic review of the HBO2 literature in order to rate the quality of evidence and generate practice recommendations for the treatment of DFUs. We selected four clinical questions for review regarding the role of HBO2 in the treatment of DFUs and analyzed the literature using patient populations based on Wagner wound classification and age of the wound (i.e., acute post-operative wound vs. non-healing wound of 30 or more days). Major amputation and incomplete healing were selected as critical outcomes of interest.

RESULTS

This analysis showed that HBO2 is beneficial in preventing amputation and promoting complete healing in patients with Wagner Grade 3 or greater DFUs who have just undergone surgical debridement of the foot as well as in patients with Wagner Grade 3 or greater DFUs that have shown no significant improvement after 30 or more days of treatment. In patients with Wagner Grade 2 or lower DFUs, there was inadequate evidence to justify the use of HBO2 as an adjunctive treatment.

CONCLUSIONS

Clinicians, patients, and policy-makers should engage in shared decision-making and consider HBO2 as an adjunctive treatment of DFUs that fit the criteria outlined in this guideline. The current body of evidence provides a moderate level of evidence supporting the use of HBO2 for DFUs. Future research should be directed at improving methods for patient selection, testing various treatment protocols and improving our confidence in the existing estimates.

Refractive change in response to acute hyperbaric stress in refractive surgery patients

PURPOSE

To determine whether acute hyperbaric stress affects visual acuity or refractive power after keratorefractive surgery.

SETTING

Clinical multiplace hyperbaric chamber and ophthalmology clinic, University of California, San Diego, California, USA.

METHODS

This prospective convenience sample study included 3 groups: 3 patients who had had bilateral myopic radial keratotomy (RK); 2 who had had bilateral myopic laser in situ keratomileusis (LASIK); and 4 control subjects who had no previous corneal refractive surgery or ocular pathology but had a myopic refractive error (-1.25 to -8.38 diopters [D]) similar to that in the treated patients before refractive surgery. One additional patient had had unilateral LASIK only and was included in the LASIK and control groups. Best spectacle-corrected visual acuity (BSCVA), manifest spherocylindrical refractive error, and intraocular pressure were measured at baseline, at 4 atmospheres absolute (atm abs), and on return to ambient pressure. Corneal pachymetry and keratometry were measured at baseline and on return to ambient pressure.

RESULTS

The mean BSCVA changed from 0.06 logMAR (20/25 Snellen equivalent) at baseline to 0.10 logMAR (20/25) at 4 atm abs in the RK group and from 0.00 logMAR (20/20) to -0.06 logMAR (20/15) in the LASIK group; it did not change in the control group. The mean refractive error changed from 0.25 D at baseline to 0.50 D at 4 atm abs in the RK group, from -0.90 to -1.02 D in the LASIK group, and from -4.58 to -4.53 D in the control group.

CONCLUSIONS

Acute hyperbaric stress did not appear to alter refractive power after corneal surgery.

Air sparging tracer test to investigate the flow path

The paper presents a useful method for investigating the flow path of the injected air, estimating the radius of influence, and assisting the design of well spacing of sparging wells. The method applies both tracer and modeling approach. A field test using helium as a tracer was conducted on an air sparging pilot. A 3-dimensional, 3-phase compositional model was utilized to simulate the air sparging process at the pilot. The model was first calibrated with the tracer concentrations observed in the field test at various locations between the air sparging well and the soil vapor extraction well. The calibrated model was then used to predict the flow path of the injected air and to simulate the water saturation distributions in the aquifer. The steady-state water saturation distributions was found useful for estimating the radius of influence of air sparging and for designing the well spacing of sparging well.

Ventriculo-peritoneal shunt performance under hyperbaric conditions

A novice scuba diver with an implanted ventriculo-peritoneal (VP) shunt inquired about the performance characteristics of his shunt while diving. A literature search revealed no information regarding shunt performance under hyperbaric conditions. The manufacturer could not certify that the shunt would function under pressure. Therefore, four VP shunts were tested according to the manufacturer's testing protocol at 1 and 4 atm abs in a multiplace hyperbaric chamber. The pressure (in mm of H2O) required to establish flow through the shunts was recorded. Trials at 1 atm abs (n = 12) and 4 atm abs (n = 12) show that all shunts performed within the pressure range specified by the manufacturer.

On estimating census undercount in small areas

"Net undercount rates in the U.S. decennial census have been steadily declining over the last several censuses. Differential undercounts among race groups and geographic areas, however, appear to persist. In the following, we examine and compare several methodologies for providing small area estimates of census coverage by constructing artificial populations. Measures of performance are also introduced to assess the various small area estimates. Synthetic estimation in combination with regression modelling provide the best results over the methods considered. Sampling error effects are also simulated. The results form the basis for determining coverage evaluation survey small area estimates of the 1900 decennial census."